Skip to main content
06 September 2026
13 January 2026

TetraScience and Thermo Fisher Collaborate to Advance Scientific AI in Biopharma

TetraScience, the Scientific Data and AI company, announced a collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, with a goal of accelerating AI across biopharma R&D and manufacturing by transforming scientific data into AI-native form and developing intelligent workflows at scal…

12 January 2026

Nona Biosciences Expands Cell Therapy Pipeline Through Link Cell Therapies Alliance

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology platforms, announced that it has entered into a multi-target antibody discovery collaboration with Link Cell Therapies. This collaboration will leverage Nona's proprietary fully human HCAb Harbour Mice…

12 January 2026

Sanofi Strengthens AI R&D Capabilities Through Expanded CytoReason Tie-Up

CytoReason, a leader in AI-powered computational disease modeling, announced the expansion of its collaboration with Sanofi for the third time. This multi-year agreement, valued at up to $16 million, further solidifies their partnership. CytoReason technology enables researchers to extract insights from molecular and…

09 January 2026

Veeva, BioMarin expand long-term enterprise partnership

Veeva Systems  and BioMarin Pharmaceutical Inc.  announced a long-term enterprise agreement that builds upon their long-standing relationship. The expanded partnership will help BioMarin increase speed, agility, operational efficiency, and optimize the healthcare professional and patient experience by further leverag…

09 January 2026

MediLink signs $570M ADC licensing agreement with Roche

MediLink Therapeutics announced that it has entered into a new collaboration and exclusive licensing agreement with Roche for the development and commercialization of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumor types. Under the terms of the agreement,…

08 January 2026

Lilly Expands Inflammation Pipeline with Ventyx Acquisition

Eli Lilly and Company  and Ventyx Biosciences, Inc. , a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, announced entry into a definitive agreement for Lilly to acquire Ventyx. Ventyx is developing a pipeline of…

08 January 2026

Helix, GSK Enter Long-Term Collaboration to Advance Genomic Research

Helix, the leading enterprise genomics company, announced a multi-year strategic collaboration with GSK, the global biopharma company. This agreement provides GSK access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas. Helix GenoSphere™ cohorts consist o…

07 January 2026

Amgen Strengthens Oncology Pipeline with Dark Blue Therapeutics Acquisition

Amgen announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.   The acquisition adds to Amgen's portfolio an investigati…

06 January 2026

Sanofi Partners with Earendil Labs to Advance AI-Discovered Bispecific Therapies

Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, announced a strategic collaboration with Sanofi to apply Earendil's discovery platform to multiple autoimmune and inflammatory disease programs. Sanofi will lead the development and worldwide commercializati…

Page 21 of 39

indojawa88sabung ayamhttps://onebaboon.com/sabung ayam terpercayahttps://elitebands.co.uk/contact/ indojawa88indojawa88indojawa88medeago.comhttps://elitebands.co.uk/live-showcase/ https://samen-veilig.nl/voorlichting-training/https://samen-veilig.nl/contact/indojawa88.fundhttps://elitebands.co.uk/blog/